Cubist Pharmaceuticals Inc (CBST.OQ)

CBST.OQ on NASDAQ Stock Exchange Global Select Market

64.80USD
1 Aug 2013
Price Change (% chg)

$2.47 (+3.96%)
Prev Close
$62.33
Open
$62.46
Day's High
$65.55
Day's Low
$62.46
Volume
382,176
Avg. Vol
329,145
52-wk High
$65.55
52-wk Low
$38.54

CBST.OQ

Chart for CBST.OQ

About

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed... (more)

Overall

Beta: 0.64
Market Cap (Mil.): $4,114.65
Shares Outstanding (Mil.): 66.01
Dividend: --
Yield (%): --

Financials

  CBST.OQ Industry Sector
P/E (TTM): 45.42 37.93 37.76
EPS (TTM): 1.37 -- --
ROI: 5.82 19.48 18.76
ROE: 10.23 20.17 19.59
Search Stocks

Cubist to pay up to $1.6 billion for two antibiotics makers

- Cubist Pharmaceuticals Inc has agreed to pay up to $1.6 billion for Trius Therapeutics Inc and Optimer Pharmaceuticals Inc, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise.

30 Jul 2013

UPDATE 2-Cubist to pay up to $1.6 bln for two antibiotics makers

* Cubist sees the sum of both deals to be accretive in 2015

30 Jul 2013

Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 billion

- Cubist Pharmaceuticals Inc said it would buy Trius Therapeutics Inc and Optimer Pharmaceuticals Inc for up to $1.62 billion to boost its antibiotics portfolio.

30 Jul 2013

CORRECTED-Cubist to buy Trius Therapeutics, Optimer Pharma for up to $1.62 bln

(Corrects paragraphs 2 and 3 to say the per-share offers include contingency payments)

30 Jul 2013

U.S. court ruling favors Cubist in patent case versus Hospira

- A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .

20 May 2013

U.S. court ruling favors Cubist in patent case vs Hospira

May 20 - A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc.

20 May 2013

Cubist bid for Optimer before sale process began: sources

NEW YORK - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

15 May 2013

Cubist bid almost $1 bln for Optimer before sale process-sources

NEW YORK, May 15 - Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.

15 May 2013

Optimer shares rise after report names Glaxo, Cubist as potential buyers

- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker.

02 Apr 2013

UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers

* Shares up 18 pct (Adds comments from an analyst, details)

02 Apr 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Factual Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks